Stonebridge Capital Advisors LLC boosted its stake in shares of GlaxoSmithKline plc (NYSE:GSK) by 7.5% in the 2nd quarter, according to its most recent disclosure with the SEC. The institutional investor owned 28,967 shares of the pharmaceutical company’s stock after acquiring an additional 2,014 shares during the period. Stonebridge Capital Advisors LLC’s holdings in GlaxoSmithKline were worth $1,159,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of GSK. Berman Capital Advisors LLC grew its stake in GlaxoSmithKline by 58.1% during the second quarter. Berman Capital Advisors LLC now owns 656 shares of the pharmaceutical company’s stock valued at $26,000 after acquiring an additional 241 shares in the last quarter. Financial Gravity Wealth Inc. grew its stake in GlaxoSmithKline by 62.7% during the second quarter. Financial Gravity Wealth Inc. now owns 799 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 308 shares in the last quarter. Princeton Global Asset Management LLC purchased a new position in GlaxoSmithKline during the first quarter valued at $37,000. Manchester Financial Inc. purchased a new position in shares of GlaxoSmithKline in the 2nd quarter worth $39,000. Finally, Westside Investment Management Inc. purchased a new position in shares of GlaxoSmithKline in the 2nd quarter worth $50,000. 11.12% of the stock is owned by institutional investors.
GSK has been the subject of a number of recent research reports. Cowen reissued a “hold” rating and issued a $45.00 price objective on shares of GlaxoSmithKline in a research note on Monday, June 10th. JPMorgan Chase & Co. reissued a “neutral” rating on shares of GlaxoSmithKline in a research note on Tuesday, August 13th. Morgan Stanley reissued an “underweight” rating on shares of GlaxoSmithKline in a research note on Monday, June 17th. Jefferies Financial Group reissued a “buy” rating on shares of GlaxoSmithKline in a research note on Thursday, August 29th. Finally, ValuEngine cut shares of GlaxoSmithKline from a “hold” rating to a “sell” rating in a research note on Tuesday, September 10th. Two investment analysts have rated the stock with a sell rating, twelve have issued a hold rating and three have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $41.79.
GlaxoSmithKline (NYSE:GSK) last released its earnings results on Wednesday, July 24th. The pharmaceutical company reported $0.78 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.64 by $0.14. The firm had revenue of $10.04 billion during the quarter, compared to analyst estimates of $9.55 billion. GlaxoSmithKline had a net margin of 13.84% and a return on equity of 175.45%. On average, equities research analysts forecast that GlaxoSmithKline plc will post 2.95 EPS for the current fiscal year.
In other news, Director Plc Glaxosmithkline bought 177,777 shares of the stock in a transaction dated Tuesday, September 10th. The stock was purchased at an average price of $45.00 per share, for a total transaction of $7,999,965.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 10.00% of the stock is currently owned by company insiders.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Further Reading: How does a dividend reinvestment plan work?
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.